Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects
Ruihua Dong,Jingcheng Chen,Nini Guo,Yingying Yang,Jingxuan Wu,Xiaoru Wang,Yuqin Song,Xueyuan Zhang
DOI: https://doi.org/10.2147/dddt.s481481
IF: 4.3188
2024-12-04
Drug Design Development and Therapy
Abstract:Ruihua Dong, 1, &ast Jingcheng Chen, 1, &ast Nini Guo, 2 Yingying Yang, 2 Jingxuan Wu, 1 Xiaoru Wang, 2 Yuqin Song, 1 Xueyuan Zhang 2 1 Phase I Clinical Trial Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China; 2 Clinical Department, CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., LTD., Shijiazhuang, Hebei Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xueyuan Zhang, Clinical Department, CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., LTD., Shijiazhuang, Hebei Province, 050035, People's Republic of China, Tel +86-311-69085585, Email Purpose: To evaluate the safety and pharmacokinetics of olaparib tablet test formulation (T) and reference formulation (R) in healthy Chinese male subjects. Subjects and Methods: This was a single-dose, randomized-sequence, two-way crossover study including three parts: part A: a safety exploration design in lower dose (n = 14, 100 mg), part B: a pivotal comparative pharmacokinetic (PK) trial under fast condition (n = 44, 150 mg) and part C: a pivotal comparative PK trial under food condition (n = 44, 150 mg). Blood samples were collected for 72 hours and the PK parameters of C max , AUC 0-t, and AUC 0-∞ were used to evaluate PK differences. Results: PK analysis of the two olaparib formulations showed that the Geometric Least Squares Mean (GLSM) ratio 90% confidence intervals for pivotal fasting C max , AUC 0-t, and AUC 0-∞ were 94.82– 108.97%, 92.94– 104.28%, and 92.81– 103.85%, respectively, and pivotal fed C max , AUC 0-t , and AUC 0-∞ were 82.78– 100.97%, 91.59– 104.67%, and 92.17– 104.76%, respectively. The 90% confidence interval of the two preparations, C max , AUC 0-t , and AUC 0-∞ , all fall within the equivalent range of 80– 125%. Both olaparib tablet formulations were well tolerated, with no serious adverse events (SAE) or adverse events (AE) causing withdrawal occurred. Conclusion: Two types of olaparib tablets were bioequivalent under both fasting and fed condition, and were generally well tolerated in healthy Chinese male subjects. Keywords: olaparib, safety, pharmacokinetics, bioequivalence, healthy Chinese male subjects Poly (ADP-ribose) polymerase (PARP) inhibitors is a type of small molecule inhibitor that specifically targets PARP1 and PARP2. 1 PARP-1 and −2 are essential for protecting DNA from radioactive and monofunctional alkylating agent's damage. One mechanism of action of PARP inhibitors is the inhibition of PARP1 and PARP2, which inhibits DNA single-strand breaks from being repaired, resulting in double-strand breaks (DSBs). Another mechanism by which PARP inhibitors cause DSBs is by trapping the PARP enzyme-DNA complex on single-strand breaks. 1,2 Healthy cells can repair DSBs via the functional homologous recombination repair mechanism, so PARP inhibitors are ineffective in them. Cells with homologous recombination deficiencies (HRD), especially pathogenic breast cancer (BRCA)-1 or BRCA-2 mutations, are more susceptible to PARP inhibitors. 2 PARP inhibitors can induce synthetic lethality in tumors harboring BRCA1/2 mutations or other homologous recombination repair (HRR) pathway deficiencies. They are promising for the treatment of several tumors. In 2014, the European Medicines Agency (EMA) approved olaparib, the first PARP inhibitor, to treat ovarian cancer. In patients with platinum-sensitive, relapsed, high-grade epithelial ovarian cancer who had responded to platinum-based treatment, olaparib had a good anti-tumor effect. 3 Patients with germline or somatic BRCA1/2 mutations showed the largest benefit, while those with wild-type BRCA showed less benefit. 4 PARP inhibitors are currently approved for the treatment of a variety of tumors, including ovarian, breast, pancreatic, and prostate cancers. The indications for PARP inhibitors are rapidly expanding, starting with monotherapy in patients with BRCA mutations and progressing to patients with other HRD and no HRD, as well as combinations with immunotherapy, targeted therapies, radiotherapy, and chemotherapy. 1,5 Olaparib's PK profile in patients showed that it was rapidly absorbed after oral administration and that a high-fat diet delayed its absorption rate but did not significantly alter the extent of absorption of olaparib. 6 Population pharmacokinetic analyses showed that patient age, gender, body weight, or race (including Caucasian, Chinese, and Japanese) were not signific -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal